Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02430714

Enrollment

629

Registered

2015-04-30

Start date

2015-05-20

Completion date

2016-11-06

Last updated

2020-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Neoplasms

Keywords

Thyroid Cancer, Lenvima, Post-marketing surveillance, LEN01T, All-Patient Investigation, Lenvatinib Mesylate

Brief summary

This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.

Interventions

DRUGLenvatinib

24mg once daily oral dosing to Unresectable thyroid cancer patients

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1\. All participants with unresectable thyroid cancer and administrated Lenvatinib.

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse events (AEs)/adverse drug reactions (ADRs)	up to 1 year

Secondary

Measure	Time frame
Overall survival (OS)	up to 1 year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026